Fulminant type 1 diabetes mellitus associated with a reactivation of Epstein-Barr virus that developed in the course of chemotherapy of multiple myeloma

Journal of Diabetes Investigation

Volumn 1, Issue 6, 2010, Pages 286-289

  Fujiya, Atsushi ^a   Ochiai, Hiroshi ^a   Mizukoshi, Toshihiro ^a   Kiyota, Atsushi ^a   Shibata, Taiga ^a   Suzuki, Atsushi ^a   Ohashi, Norimi ^a   Sobajima, Hiroshi ^a  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Epstein Barr virus; Fulminant type 1 diabetes mellitus; Multiple myeloma

Indexed keywords

C PEPTIDE; DEXAMETHASONE; DOXORUBICIN; GLUCOSE; HEMOGLOBIN A1C; IMMUNOGLOBULIN M; INSULIN; MELPHALAN; PANCREAS ENZYME; PREDNISOLONE; SULPERAZON; VINCRISTINE; VIRUS ANTIBODY; VIRUS CAPSID ANTIGEN;

AGED; ANTIBODY TITER; ARTERIAL GAS; ARTICLE; CANCER CHEMOTHERAPY; CASE REPORT; DIABETIC KETOACIDOSIS; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS INFECTION; FEMALE; FEVER; GALLBLADDER DISEASE; GLUCOSE BLOOD LEVEL; HEPATOMEGALY; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; METABOLIC ACIDOSIS; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REHYDRATION; SIDE EFFECT; SKIN BIOPSY; VIRUS REACTIVATION;

EID: 79953752968     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2010.00061.x     Document Type: Article

References (15)

1. Imagawa A, Hanafusa T, Miyagawa J, et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 2000; 342: 301-307.
2. Imagawa A, Hanafusa T, Miyagawa J, et al. A proposal of three distinct subtypes of type 1 diabetes mellitus besed on clinical and pathological evidence. Ann Med 2000; 32: 539-543.
3. Sano H, Terasaki J, Tsutsumi C, et al. A case of fluminant type type 1 diabetes mellitus after Influenza B infection. Diabetes Res Clin Pract 2008; 79: e8-e9.
4. Akatsuka H, Yano Y, Gabazza E, et al. A case of fulminant type 1 diabetes with coxackie B4 virus infectin diagnosed by elevated serum levels of neutralizing antibody. Diabetes Res Clin Pract 2009; 84: e50-e52.
5. Goto A, Takahashi Y, Kishimoto M, et al. A case of Fulminant Type 1 Diabetes Associated With Significant Elevation of Mumps Titers. Endocr J 2008; 55: 561-564.
6. Imagawa A, Hanafusa T, Uchigata Y, et al. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 2003; 25: 2302-2307.
7. Imagawa A, Hanfusa T. Pathogenesis of Fulminant Type 1 Diabetes. Rev Diabet Stud 2006; 3: 169-177.
8. Nakanishi K, Kobayashi T, Murase T, et al. Association of HLA-A24 with complete B-cell destruction in IDDM. Diabetes 1993; 42: 1086-1093.
9. Kawabata Y, Ikegami H, Awata T, et al. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia 2009; 52: 2513-2521.
10. Kawasaki E, Matsuura N, Eguchi K. Type 1 diabetes in Japan. Diabetologia 2005; 49: 828-836.
11. Helmke K, Otten A, Willems WR, et al. Islet cell antibodies and the development of diabetes mellitus in relation to mumps infection and mumps vaccination. Diabetologia 1986; 29: 30-33.
12. Bodanski HJ, Grant PJ, Dean BM, et al. Islet-cell antibodies and insulin autoantibodies in association with common viral infections. Lancet 1986; 2: 1351-1353.
13. Champsaur H, Bottazzo GF, Bertrams J, et al. Virologic, immu-nologic and genetic factors in insulin-dependent diabetes mellitus. J Pediatrics 1982; 100: 15-20.
14. Imagawa A, Hanfusa T, Makino H, et al. High titers of IgA antibodies to enterovirus in fulminant type 1 diabetes. Diabetologia 2005; 48: 290-293.
15. Yang Z, Chen M, Wu R, et al. Suppression of autoimmune diabetes by viral IL-10 gene transfer. J Immunol 2002; 168: 6479-6485.